ABSTRACT
Stage of disease at diagnosis and histologic type according to WHO classification are the most important prognostic factors for thymoma and complete surgical resection represents a crucial point for disease free survival. When surgery is not feasible, neoadjuvant or palliative chemotherapy, is the most appropriate treatment because of the high chemosensitivity of the thymoma. The role of predictive factors to response of treatment seems relevant: the presence of modifications of tumor related genes and expression of different thymoma cell receptors could allow to identify subsets of patients who can benefit from target therapies, with the aim of optimizing treatments and improving survival.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Thymoma/drug therapy , Thymus Neoplasms/drug therapy , Cell Differentiation , Cisplatin , Combined Modality Therapy , Cyclophosphamide , Disease-Free Survival , Doxorubicin , Etoposide , Humans , Neoplasm Proteins/analysis , Neoplasm Proteins/genetics , Neoplasm Staging , Palliative Care , Thymectomy , Thymoma/complications , Thymoma/genetics , Thymoma/pathology , Thymoma/radiotherapy , Thymoma/surgery , Thymus Neoplasms/complications , Thymus Neoplasms/genetics , Thymus Neoplasms/pathology , Thymus Neoplasms/radiotherapy , Thymus Neoplasms/surgery , VincristineABSTRACT
The objective of this observational study was the early evaluation of the impact, a week after the first administration of epoetin alfa 40000 U once weekly and i.v. dose of 62.5 mg sodium ferric gluconate for seven days in improving hemoglobin levels in cancer patients affected by mild/moderate or severe anemia during chemotherapy. Twenty patients affected by solid tumors who received epoetin alfa 40000 U once weekly and daily i.v. sodium ferric gluconate for one week were evaluated: 90% of the patients showed hemoglobin increase, with a median level of hemoglobin increase of 0.73 g/L from baseline, and 50% of them showing a hemoglobin increase > 1 gr/L. The treatment was well tolerated and no adverse event was observed. The early increase of hemoglobin level from baseline is interesting and suggestive for the possibility of achieving an adequate hemoglobin level with a short-term treatment. It is still necessary to further explore the real need of iron supplementation to maintain adequate erythropoiesis prior and during epoetin therapy.
Subject(s)
Antineoplastic Agents/adverse effects , Erythropoietin/therapeutic use , Hematinics/therapeutic use , Hemoglobins/drug effects , Iron/therapeutic use , Neoplasms/blood , Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Anemia/drug therapy , Anemia/prevention & control , Antineoplastic Agents/therapeutic use , Dietary Supplements , Epoetin Alfa , Erythropoietin/administration & dosage , Female , Humans , Infusions, Intravenous , Iron/administration & dosage , Iron/metabolism , Male , Middle Aged , Recombinant Proteins , Treatment OutcomeABSTRACT
In ninety's breast cancer was first in Europe for the use of high-dose chemotherapy with autologous hematopoietic stem cell transplantation in solid tumors in adults. Some phase II trials of high-dose chemotherapy showed high response rates and prolonged progression free survival in selected metastastic breast cancer patients. Few large, powerful randomized phase III studies comparing this approach with conventional chemotherapy have been completed: some studies showed a better progression free survival in favor of high dose chemotherapy, but no statistically significant difference in overall survival was observed. Many variables inside high dose chemotherapy program need to be considered. The identification of subsets of breast cancer patients who can benefit from high-dose chemotherapy is essential: high-dose chemotherapy should be included in a global treatment strategy, evaluating the integration with innovative treatment modalities, with the aim of eradicating the minimal residual disease in breast cancer patients achieving complete response after high dose chemotherapy.
Subject(s)
Antineoplastic Agents/administration & dosage , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Female , Humans , Neoplasm Metastasis , Randomized Controlled Trials as TopicABSTRACT
PURPOSE: We determined the activity and toxicity of gemcitabine plus cisplatin in patients with inoperable or metastatic transitional cell carcinoma of the urinary tract. MATERIALS AND METHODS: A total of 54 patients with transitional cell carcinoma, measurable disease and Eastern Cooperative Oncology Group performance status 2 or greater were enrolled in this multicenter phase II trial. Previous adjuvant or neoadjuvant therapy for locally advanced disease was acceptable if it had been completed more than 1 year before study entry. Every 4 weeks patients received 1,000 mg./m.2 gemcitabine intravenously on days 1, 8 and 15, and 70 mg./m.2 cisplatin intravenously on day 2. RESULTS: All patients were evaluable for response and toxicity. Notably only 7 of the 54 patients (13%) previously received chemotherapy in an adjuvant or neoadjuvant setting. Overall we observed 26 objective responses (48%), of which 15% were complete. Median time to progression was 23 weeks and median survival was 54 weeks. Treatment was well tolerated. The main toxicities were leukopenia (grade 3 in 28% and grade 4 in 11% of patients), anemia (grade 3 in 34% and grade 4 in 6%) and thrombocytopenia (grade 3 in 14% and grade 4 in 6%). Other relevant side effects were nausea and vomiting in 20% of cases, fever in 24%, alopecia in 22%, renal failure in 7.4% and mucositis in 2%. CONCLUSIONS: Combined cisplatin plus gemcitabine is highly active in advanced transitional cell carcinoma of the urinary tract with manageable toxicity. The response rate, time to treatment failure and overall survival appeared to be comparable to those achieved with combined methotrexate, vinblastine, doxorubicin and cisplatin. Conversely toxicity appeared lower. Evaluation of this regimen in randomized studies with methotrexate, vinblastine, doxorubicin and cisplatin is strongly suggested.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Transitional Cell/drug therapy , Urologic Neoplasms/drug therapy , Aged , Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Agents/administration & dosage , Carcinoma, Transitional Cell/pathology , Carcinoma, Transitional Cell/secondary , Cisplatin/administration & dosage , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Female , Humans , Male , Neoplasm Staging , Urologic Neoplasms/pathology , GemcitabineABSTRACT
Anaplastic carcinoma, insular carcinoma and medullary carcinoma (both familiar and sporadic forms) represent the 7-25% of all thyroid tumors. Anaplastic carcinoma is one of most aggressive human tumors and the therapeutic options proposed have failed to improve the prognosis of these patients. Insular carcinoma is a not well known thyroid neoplasia described for the first time in 1984 and showing intermediate biological behaviour between differentiated and anaplastic forms. Medullary carcinoma arises from parafollicular"C" cells of the gland and then may be considered a neuroendocrine tumor. Choice therapy is surgery, tiroxine is only substitutive, familiar screening is mandatory. Chemotherapy (dacarbazine or cisplatin and doxorubicine), radiotherapy and recently octreotide anologues, may be useful for relapsing not operable forms.
Subject(s)
Carcinoma, Medullary , Thyroid Neoplasms , Adolescent , Adult , Carcinoma, Medullary/diagnosis , Carcinoma, Medullary/epidemiology , Carcinoma, Medullary/etiology , Carcinoma, Medullary/therapy , Female , Humans , Male , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/epidemiology , Thyroid Neoplasms/etiology , Thyroid Neoplasms/therapyABSTRACT
Differentiated thyroid carcinomas are TSH-dependent tumors induced by genetic and environmental factors. They may be found on 3-12% of single thyroid lesions. Females are more affected than males (F:M 3:1). The combined action of genetic and environmental factors induces the development of these tumors. The cornerstone of diagnostic evaluation is Fine Needle Aspiration (FNA). Size tumors > 2.5 cm and age > 45 aa are unfavorable prognostic factors. Radical surgery is the first choice therapy followed by hormone suppressive therapy and/or I131. Follow-up is based on WBS and serum Tg evaluation. Moreover recombinant TSH offers a new approach in the field of relapse diagnosis and therapy.
Subject(s)
Carcinoma , Neoplasms, Hormone-Dependent , Thyroid Neoplasms , Carcinoma/diagnosis , Carcinoma/etiology , Carcinoma/therapy , Female , Humans , Male , Neoplasms, Hormone-Dependent/diagnosis , Neoplasms, Hormone-Dependent/etiology , Neoplasms, Hormone-Dependent/therapy , Prognosis , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/etiology , Thyroid Neoplasms/therapyABSTRACT
Primary non-Hodgkin's lymphomas (NHL) of the breast represent less than 3% of extranodal NHL; in comparison to extranodal NHL at other sites, they are characterized by rapid progression and worse prognosis. We report a case of primary NHL of the breast treated, after surgery, with a sequential combination of chemotherapy and radiotherapy. Literature data suggest that the most important factors in therapeutic decisions making are the initial stage of the disease and the histological subtype.
Subject(s)
Breast Neoplasms/surgery , Lymphoma, Non-Hodgkin/surgery , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Combined Modality Therapy , Female , Humans , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/pathology , Lymphoma, Non-Hodgkin/radiotherapy , PrognosisABSTRACT
In the present report, we retrospectively analyzed the impact of the timing of surgery during menstrual cycle on disease-free and overall survival of 248 premenopausal patients with stage I/II breast cancer who underwent surgery followed by anthracycline-containing adjuvant chemotherapy. With a median follow-up of 5 years, no statistically significant differences were observed in disease-free or overall survival between women operated upon during the follicular (days 0-14) and the luteal (days 15-32) phase of the menstrual cycle. The impact on disease-free and overall survival of lymph-node status, tumor size and hormone receptor expression, but not of the phase of the menstrual cycle at the time of surgery, was confirmed by univariate and multivariate analysis. However, when combined with hormone receptor status, the phase of the menstrual cycle at the time of surgery proved useful to better define the prognosis of primary breast cancer patients, with significantly longer disease-free and overall survival for patients operated upon during the follicular phase and with positive hormone receptors.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/surgery , Menstrual Cycle , Premenopause , Adult , Breast Neoplasms/pathology , Disease-Free Survival , Female , Follow-Up Studies , Humans , Middle Aged , Multivariate Analysis , Prognosis , Proportional Hazards Models , Prospective Studies , Retrospective Studies , Survival AnalysisABSTRACT
We report a case of primary squamous cell carcinoma of the breast in a 58 years old woman. The diagnosis of this rare tumor is possible after excluding a skin primary lesion or an epidermoid cancer of a distant site. In reviewing the reported cases we didn't find any significant prognostic difference between this form and the breast adenocarcinoma with squamous metaplasia.
Subject(s)
Breast Neoplasms/diagnostic imaging , Carcinoma, Squamous Cell/diagnostic imaging , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Female , Humans , Mammography , Mastectomy, Modified Radical , Metaplasia/pathology , Middle AgedABSTRACT
The aim of this study was to evaluate the efficacy and safety of gemcitabine, a pyrimidine antimetabolite, in the treatment of advanced transitional cell carcinoma of the urinary tract. 35 patients with unresectable or metastatic transitional cell carcinoma of the urinary tract previously treated with a platinum-based regimen were studied. Gemcitabine was administered at a dosage of 1200 mg/m2 as a 30-min intravenous infusion on days 1, 8 and 15, repeated every 28 days. 31 patients were evaluable for efficacy. 4 patients achieved a complete response (12.9%), 3 a partial response (9.6%) and 13 (42%) were stable for at least 4 weeks (overall response 22.5%; 95% confidence interval 8-37%). The median response duration was 11.8 months (range 3.6-17.7 + months) and median survival for all patients entered was 5 months (range 2-21 + months). 2 patients with complete response are still alive with no evidence of disease after 14 and 21 months. Gemcitabine also provided subjective symptomatic relief from pain, cystitis, dysuria, haematuria and peripheral oedema. Patients experienced little WHO grade 3-4 toxicity, with anaemia in 8 patients (23%), thrombocytopenia in 5 (14.2%), leucopenia in 4 (11.4%) and neutropenia in 7 (20%). WHO grade 3-4 hepatic toxicity occurred in 4 patients (11.4%) and transient elevations of transaminase was noted in 3 (8.6%). No patient had WHO grade 3-4 elevation of serum creatinine level. There was no WHO grade 4 symptomatic toxicity and no alopecia was noted. Transient influenza symptoms with gemcitabine occurred in 18 patients (51.4%) with 13 patients (37.1%) experiencing fever (2.9% WHO grade 3). In conclusion, gemcitabine is an new active agent for the treatment of transitional cell carcinoma of the urinary bladder with a mild toxicity profile; it warrants further investigation in combination with cisplatin in chemotherapy naive patients.
Subject(s)
Carcinoma, Transitional Cell/drug therapy , Cisplatin/therapeutic use , Deoxycytidine/analogs & derivatives , Urologic Neoplasms/drug therapy , Adult , Aged , Deoxycytidine/adverse effects , Deoxycytidine/therapeutic use , Female , Hematologic Diseases/chemically induced , Humans , Influenza, Human/chemically induced , Infusions, Intravenous , Male , Middle Aged , Treatment Outcome , GemcitabineABSTRACT
This double-blind, double-dummy, randomized study compared the 24 h efficacy and safety of granisetron alone (3 mg i.v. over 30 s) or in combination with methylprednisolone (250 mg i.v. twice daily) in preventing nausea and vomiting in 308 patients (254 males) receiving high-dose cisplatin (100 mg/m2 or above) for mainly lung, and head and neck cancers. All patients received oral follow-on therapy comprising oral granisetron and methylprednisolone during the following 6 days. Primary efficacy variables were the proportions of complete responses (CR; no vomiting, no worse than mild nausea, no rescue and no withdrawal), no vomiting and no nausea over the first 24 h following initiation of the cisplatin infusion. The two treatment groups were well matched for demographics, cancer site, cisplatin dose and duration of infusion. Granisetron plus methylprednisolone was significantly more effective than granisetron alone for all primary efficacy variables: CR 78 versus 59% (p<0.001), no vomiting 80 versus 61% (p<0.001) and no nausea 74 versus 57% (p<0.002). Significantly more patients receiving the combination were free of any emetic symptoms (74 versus 54%, p<0.001). Significantly fewer patients receiving combination therapy also required rescue therapy with i.v. granisetron (12.2 versus 21.7%, p=0.026). During the follow-on period, complete response rates varied day by day from 50 to 71%. Both treatments were well tolerated, with constipation, abdominal pain and headache as the most frequent adverse events.
Subject(s)
Antiemetics/therapeutic use , Antineoplastic Agents/adverse effects , Cisplatin/adverse effects , Granisetron/therapeutic use , Methylprednisolone/therapeutic use , Vomiting/prevention & control , Abdominal Pain/chemically induced , Adolescent , Adult , Aged , Antiemetics/adverse effects , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Blood Urea Nitrogen , Cisplatin/administration & dosage , Cisplatin/therapeutic use , Constipation/chemically induced , Dose-Response Relationship, Drug , Double-Blind Method , Drug Therapy, Combination , Female , Follow-Up Studies , Granisetron/adverse effects , Headache/chemically induced , Humans , Leukopenia/chemically induced , Male , Methylprednisolone/adverse effects , Middle Aged , Nitrogen/blood , Treatment Outcome , Vomiting/chemically induced , Vomiting/drug therapySubject(s)
Breast Neoplasms/drug therapy , Hematopoietic Stem Cell Transplantation , Female , Forecasting , Humans , PrognosisABSTRACT
BACKGROUND: Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent. Administration by continuous infusion and hematopoietic support have rendered dose intensification regimens possible by reducing both hematologic and non-hematologic toxicities. The optimal dose and schedule of ifosfamide when given at high doses remain to be defined. In a previous phase I study, we demonstrated the feasibility of a continuous infusion (c.i.) high-dose ifosfamide (HDI) regimen in the ambulatory setting for patients with advanced solid tumors. The objective of the present phase II study was to assess the antitumor activity and toxicity of such a schedule in patients with advanced pretreated STS. PATIENTS AND METHODS: Thirty-eight patients with advanced and/or metastatic STS, all pretreated with an anthracycline with or without standard-dose ifosfamide, were treated. Ifosfamide was given by c.i. at a dose of 3.5 g/m2/day over four consecutive days, with equidose mesna uroprotection over five days. G-CSF was added at a dose of 200 micrograms/m2/day subcutaneously from day 6 to day 12. Cycles were repeated every three weeks in the outpatient setting. RESULTS: A total of 159 cycles of therapy were given (median 4 per patient, range 3-6). Treatment compliance was generally satisfactory. The major toxicity was hematologic, with six febrile neutropenic episodes requiring hospitalisation and parenteral antibiotics. Acute renal failure occurred in one patient after three cycles of therapy; central nervous system toxicity was mild. An overall response rate of 39% was observed (95% confidence interval, 26% to 55%), with one complete and 14 partial remissions. All but one of the responder patients had previously received standard-dose ifosfamide. The median response duration was nine months (range 5-21+ months), and the overall median survival ranged from 6-30+ months (median 13 months). CONCLUSIONS: High-dose ifosfamide is an active regimen in anthracycline-pretreated STS. Future clinical trials should be aimed at evaluating the impact of different administration schedules on clinical response and outcome. The potential role of HDI as front-line chemotherapy as well as in the adjuvant treatment of STS needs to be investigated in randomized trials.
Subject(s)
Antineoplastic Agents, Alkylating/administration & dosage , Ifosfamide/administration & dosage , Sarcoma/drug therapy , Soft Tissue Neoplasms/drug therapy , Adult , Aged , Antineoplastic Agents, Alkylating/adverse effects , Drug Administration Schedule , Female , Granulocyte Colony-Stimulating Factor/administration & dosage , Humans , Ifosfamide/adverse effects , Infusions, Intravenous , Male , Mesna/administration & dosage , Middle Aged , Treatment OutcomeABSTRACT
AIMS AND BACKGROUND: Doxifluridine (RO 21-9738, 5'-dFUR) is a fluoropyrimidine derivative with proven antitumor activity in different experimental models. On the basis of experimental evidence, several clinical trials have been carried out to define the optimal 5'-dFUR dose and route of administration. In general, the maximum monthly dose of 5'-dFUR was 36-38 g. According to these clinical data, we explored the feasibility of a combination of 5'-dFUR and interferon-alpha-2a (IFN-alpha-2a). The aim of the protocol was to confirm the maximum tolerated dose (MTD) of the drug in combination with a settled dose of IFN alpha 2a. METHODS: An open-label phase I study with intravenous 5'-dFUR was carried out in 12 patients with a histologically proven diagnosis of advanced gastrointestinal or breast cancer refractory to previous conventional hormone-chemotherapy. Escalating doses of 5'-dFUR were administered as a 2-h intravenous infusion, once a week for at least 4 weeks in groups of 3 patients. IFN-alpha-2a was administered as an intramuscular injection of 3 MU 3 times a week for 4 consecutive weeks. Physical and laboratory parameters were assessed at baseline and then weekly until the end of treatment. RESULTS: The treatment with 5'-dFUR was stopped at 5 g/m2, since this level corresponded to the maximum monthly dosage reported in the literature (36-38 g). No severe toxicity was recorded up to this drug level. CONCLUSIONS: The combination of 5'-dFUR plus IFN-alpha-2a was well tolerated at the level of 5 g/m2. Although the MTD was not reached, it can be stated that the dosage administered in this study could be explored in a larger trial.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Floxuridine/administration & dosage , Interferon-alpha/administration & dosage , Neoplasms/drug therapy , Adult , Aged , Female , Humans , Interferon alpha-2 , Male , Middle Aged , Recombinant ProteinsABSTRACT
Non-Hodgkin lymphomas (NHL) of the Central Nervous System (CNS) are rare but they nonetheless constitute a clinical, biological and therapeutic problem of great interest. Primary lymphomas of the CNS account for 2% of all malignant lymphomas and for 0.3-1.5% of all intracranial tumors. Surgery and radiotherapy afford only poor control of the disease. The most satisfactory results have been achieved with combination therapy, surgery + radiotherapy + chemotherapy, but the optimal combination has still to be devised. Secondary neuromeningeal involvement affects a fair number of patients with systemic NHL. The symptoms are broadly the same as in CNS NHL and the treatment as problematic. There have recently been suggestions that the onset of CNS NHL may be exacerbated by immunodeficiency states such as occur in patients who have undergone organ transplantation, in autoimmune disease and, still more recently, in the acquired immunodeficiency syndrome (AIDS). The frequency of these tumors is anyway on the increase and a better insight into the disease in essential.
Subject(s)
Brain Neoplasms/therapy , Lymphoma, Non-Hodgkin/therapy , Acquired Immunodeficiency Syndrome/complications , Adult , Autoimmune Diseases/complications , Brain Neoplasms/complications , Brain Neoplasms/pathology , Combined Modality Therapy , Female , Humans , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/pathology , MaleABSTRACT
Between 1987-1988 we treated, in a cooperative study, 13 patients in blast crisis of CGL according to Koller and Miller's regimen. We observed no return to the chronic phase of the disease, while some patients suffered major drug-induced side effects. Six patients in accelerated phase were treated with the same combination therapy. All of them responded with a return to the chronic phase for a median of 4.5 months. In our hands the combination of plicamycin and hydroxyurea was ineffective in patients with CGL in blast crisis. This regimen could deserve further evaluation in patients with CGL in acceleration.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Blast Crisis/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Leukemia, Myeloid, Accelerated Phase/drug therapy , Adult , Aged , Female , Humans , Hydroxyurea/administration & dosage , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Male , Middle Aged , Plicamycin/administration & dosageABSTRACT
In an ongoing phase II study we are evaluating the role of alpha-2b recombinant interferon in Hodgkin's disease; the study design includes patients with high-risk parameters who are treated by combination chemotherapy MOPP, ABVD, MOPP + ABVD or equivalent combinations. At the end of the therapeutic program which could include also radiotherapy, patients will be randomly assigned to receive alpha-2b interferon at 3 MU/day over 3 months and then 3 MU/three times/week over 9 months or no further treatment. Up to September 1989, 107 patients were randomized; evaluable patients with a minimum follow-up of 3 months are 95, 56 in the arm of interferon and 39 in the arm of no further treatment. The results are preliminary and differences could not be disclosed between the two arms concerning either the relapse rate or the incidence of infections. Tolerance and toxicity due to alpha-2b interferon in patients with Hodgkin's disease could be defined as acceptably good considering that mild and reversible hematological toxicity was experienced in 12 (21%) patients; objective clinical toxicity was recorded in 4 (7%) patients although 7 (12%) patients refused to continue the treatment. Definite conclusions will be drawn when 100 patients per arm become evaluable.
Subject(s)
Hodgkin Disease/drug therapy , Interferon-alpha/therapeutic use , Adult , Drug Evaluation , Female , Humans , Interferon alpha-2 , Male , Recombinant ProteinsABSTRACT
Two patients affected by severe hypogammaglobulinemia classified as CVI were studied. Both patients showed an increase in peripheral T cells and a normal or elevated number of surface immunoglobulin-bearing cells (sIg+); the T cell subsets showed a decrease of CD4 and an increment of CD8 cells with an inversion of the CD4/CD8 ratio. Patient peripheral blood mononuclear cells (PBMC) did not proliferate after Staphylococcus aureus Cowan I (SAC) activation. Moreover, patient PBMC were not able to differentiate into plaque - forming cells (PFC) either spontaneously or after pokeweed mitogen (PWM) stimulation. The immunoglobulin synthesis from patient PBMC stimulated in vitro by PWM was very little as compared to controls. When isolated patient B cells were cultured in the presence of exogenous B cell growth factor (BCGF) and BCGF plus anti-mu and anti-delta antibodies, no proliferation was observed. Taken together the results concerning B cell function of our CVI patients indicate the presence of an intrinsic defect of B cells. These cells are normal in number, but they are not able to leave the resting state, enter the activation state, proliferate and differentiate into Ig secreting cells. Moreover the alteration of the T cell subset proportions seems to suggest an impaired cooperation between B and T cells.